Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915225 · ClinicalTrials.gov registry record
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
A clinical trial of Cholangiocarcinoma and Colorectal Neoplasms, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT01915225: Recruiting study of Cholangiocarcinoma and Colorectal Neoplasms, sponsored by National Cancer Institute (NCI).
NCT01915225 is a study of Cholangiocarcinoma and Colorectal Neoplasms that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,800 participants, above the 356-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (406% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01915225, a study of Cholangiocarcinoma and Colorectal Neoplasms, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC). Objectives: \- To collect tissue samples for use in studying new ways to treat tumors. Eligibility: * Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC. * Children under the age of 18 but who are older than 2 years of age are eligible to be enrolled on the research sample collection portion of this study if they will have a biopsy or surgery as part of their medical care. Design: * Before their procedure, participants will have a small blood sample taken. * Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3-4 hours. * For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis. * Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.
Primary Outcome
Identification of novel molecular and biologic therapeutic targets
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2013-07-21 |
What NCT01915225 shows while recruiting
NCT01915225 is an observational study that tracks outcomes without assigning an intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 356-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (406% higher).
The record links to 5 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT01915225 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01915225 about?
NCT01915225 is a clinical study titled "Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer". Background: \- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to ha...
What is the current status of trial NCT01915225?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2013-07-21.
What conditions does trial NCT01915225 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Colorectal Neoplasms, Pancreas Cancer, Bile Duct Cancer, Gastric Neoplasms.
Who is sponsoring clinical trial NCT01915225?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01915225 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01915225's enrollment target sits among peer trials
1,800 2nd of 60 the highest of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI